News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
The country is sixth among the most affected countries by active cases
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
First launches expected in H1 2022
Ram’s appointment follows the launch of the CDI India division in October 2021.
Subscribe To Our Newsletter & Stay Updated
